科學家發現影響癌症治療效果的蛋白質
Scientists identify protein that impacts cancer treatment effectiveness
Updated at: June 3, 2026 at 01:45 AM
癌症研究正經歷一場靜悄悄的革命。
Cancer research is undergoing a quiet revolution.
儘管科學家已花費數十年解碼人類基因組，但他們現在正將焦點轉向「蛋白質組」——即實際驅動癌細胞行為的複雜蛋白質機制。
While scientists have spent decades decoding the human genome, they are now focusing on the 'proteome'—the complex machinery of proteins that actually drive cancer cell behavior.
近期的研究已確認了特定的「開關」蛋白質，它們充當了治療有效性的守門人。
Recent studies have identified specific 'switch' proteins that act as gatekeepers for treatment effectiveness.
例如，NFIL3 蛋白質被發現與 CAR T 細胞疲竭（exhaustion）有關，這種情況下免疫細胞會失去對抗腫瘤的效力。
For example, the protein NFIL3 has been linked to CAR T-cell exhaustion, where immune cells lose their potency against tumors.
透過抑制這種蛋白質，研究人員成功地讓免疫細胞在更長的時間內保持「充電」狀態。
By disabling this protein, researchers have successfully kept immune cells 'recharged' for longer periods.
同樣地，科學家發現 IMPACT 蛋白質可以揭開癌細胞的偽裝，使其更易被免疫系統識別。
Similarly, scientists discovered that the IMPACT protein can unmask cancer cells, making them more visible to the immune system.
其他如 p300 之類的蛋白質則握有克服化療抗藥性的關鍵。
Other proteins, like p300, hold the key to overcoming chemotherapy resistance.
研究人員不再只是開發全新的毒性藥物，而是學習如何對這些蛋白質進行「撥動開關」，從而讓腫瘤重新對現有的治療方式產生敏感。
Instead of developing entirely new, toxic drugs, researchers are learning how to 'flip the switch' on these proteins to re-sensitize tumors to existing treatments.
這種精準的方法使我們從廣譜攻擊轉向高度針對性的干預。
This precision approach moves us away from broad-spectrum attacks toward highly specific interventions.
藉由理解這些蛋白質如何主導細胞生存，我們正進入一個醫學能有效「重組」癌症環境的時代，將抗藥性腫瘤變回脆弱的弱點，並賦予免疫系統決定性的作戰機會。
By understanding how these proteins dictate cellular survival, we are entering an era where medicine can effectively 'rewire' the cancer environment, turning resistant tumors back into vulnerabilities and giving the immune system a decisive fighting chance.
